<DOC>
	<DOCNO>NCT01185639</DOCNO>
	<brief_summary>This protocol single arm phase II multi-center trial evaluate efficacy Stereotactic Body Radiation Therapy ( SBRT ) patient oligometastatic non-small cell lung cancer ( NSCLC ) response stable disease 4 cycle first-line chemotherapy . The core hypothesis test SBRT 4 cycle first-line chemotherapy feasible , safe , provide durable local control treat lesion improves time progression compare historical control . Patients eligible enrollment metastatic NSCLC ≤5 lesion amenable SBRT .</brief_summary>
	<brief_title>Stereotactic Body Radiation Therapy ( SBRT ) Metastatic Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Adrenal Gland Neoplasms</mesh_term>
	<criteria>General Patients AJCC sixth edition metastatic nonsmall cell lung carcinoma Pathologic diagnosis stage 4 nonsmall cell lung cancer prior enrollment . Patients must response stable disease RECIST criterion 4 cycle firstline chemotherapy Maximum number lesion per patient 5 total . . Patients solitary brain metastasis previously treat surgery stereotactic radiosurgery ( +/ WBRT ) currently control time study enrollment also eligible . Patients history brain metastasis must MRI show active brain metastasis within 80 day study enrollment . Patients history brain metastasis may 5 extracranial site disease except untreated primary tumor section 3.1.3.3 also apply . Patients newly diagnose stage IV NSCLC untreated primary must 3 active extracranial metastatic lesion primary site regional lymph node . Age ≥ 18 year old Performance Status 02 ( ECOG ) A sign study specific consent form require . Lung ( applies patient active lung lesion ) Patients 3 lung lesion Local failure surgical resection consider metastatic lesion purpose protocol inclusion . All lung lesion must visible CT image Cumulative diameter lung lesion must &lt; 7cm Patients may active mediastinal disease single mediastinal nodal station he/she receive prior mediastinal RT Must meet criterion regard status primary tumor site describe section 3.1.9 . Must able anticipate achieve SBRT dosimetry guideline Must adequate lung function define within 90 day enrollment : ( 1 ) Forced Expiratory Volume 1 second ( FEV1 ) &gt; 30 % predict &gt; 800 Ml , ( 2 ) diffusing capacity lung carbon monoxide ( DLCO ) &gt; 30 % predict ( 3 ) evidence actively worsen respiratory status Liver ( applies patient active liver lesion Patients 3 liver lesion All active liver lesion must discrete CT MRI image Combined diameter liver lesion must &lt; 6cm Must able anticipate achieve SBRT plan per dosimetry guideline liver . Liver function test ( AST , ALT , total bilirubin ) within ≤ 3 time upper limit normal ( ULN ) Serum Albumin must &gt; 2.5g/dL Patients active ascites . Adrenal Gland Unilateral adrenal disease Must able anticipate achieve SBRT plan per dosimetry guideline . Bone Lesions Treatment bone lesion permissible anticipated dosimetry guideline meet . Spine Paraspinal lesion Patients 3 vertebrae paraspinal site involve ( involved vertebral body paraspinal site score 1 site disease ) Must clinical radiographic evidence spinal cord compression If spinal metastasis within previously irradiate field , must 6 month interval prior radiation course study enrollment Prior spinal cord maximum dose level vertebral disease must ≤50Gy Primary tumor progression firstline chemotherapy Patients complete response firstline chemotherapy measurable target SBRT &gt; 5 metastatic lesion &gt; 3 metastatic lesion patient untreated primary site ineligible ( ipsilateral hilar mediastinal lymph node consider part untreated primary site count metastatic lesion ) Solitary brain metastasis untreated node positive primary tumor , without extracranial metastasis amenable SBRT ineligible Retreatment previously irradiate tumor exclude per 3.1.9.2 . Mediastinal lymph node involve multiple mediastinal nodal station N3 disease ineligible . Pleural effusion know malignant visible chest xray . Untreated brain metastasis Bilateral adrenal metastasis Metastases site consider amenable SBRT Patients liver metastases receive prior upper abdominal radiation Prior radiation spine ( commonly treatment primary lung cancer ) , receive &gt; 50Gy spinal cord level current vertebral metastasis Clinical radiographic evidence spinal cord compression ineligible Patients serious , uncontrolled , concurrent infection ( ) . Weight loss ( &gt; 10 % body weight ) prior 3 month . Pregnant lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>lung cancer</keyword>
	<keyword>metastatic</keyword>
	<keyword>SBRT</keyword>
	<keyword>Stereotactic body radiation therapy</keyword>
	<keyword>liver</keyword>
	<keyword>spine</keyword>
	<keyword>adrenal</keyword>
	<keyword>bone cancer</keyword>
	<keyword>Spinal Column</keyword>
</DOC>